Publications by authors named "H Koegler"
Background: FOOTPRINTS is a prospective, longitudinal, 3-year study assessing the association between biomarkers of inflammation/lung tissue destruction and chronic obstructive pulmonary disease (COPD) severity and progression in ex-smokers with mild-to-severe COPD. Here, we present baseline characteristics and select biomarkers of study subjects.
Methods: The methodology of FOOTPRINTS has been published previously.
A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.
Chronic Obstr Pulm Dis
October 2020
Background: Risk factor identification is a proven strategy in advancing treatments and preventive therapy for many chronic conditions. Quantifying the impact of those risk factors on health outcomes can consolidate and focus efforts on individuals with specific high-risk profiles. Using multiple risk factors and longitudinal outcomes in 2 independent cohorts, we developed and validated a risk score model to predict mortality in current and former cigarette smokers.
View Article and Find Full Text PDFArticle Synopsis
- Chronic obstructive pulmonary disease (COPD) affects a significant number of individuals without perfect spirometric results, highlighting a need for broader diagnostic criteria incorporating various types of evidence, including environmental factors and imaging.
- The study utilized data from the COPD Genetic Epidemiology study (COPDGene) to analyze 8784 current and former smokers, assessing symptoms, CT imaging, and spirometry to better categorize COPD and predict disease progression.
- The revised diagnostic criteria suggested that 82% of participants could be diagnosed with some form of COPD, significantly more than the 46% identified by current Global initiative for obstructive Lung Disease (GOLD) standards.
Background: Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of nintedanib versus placebo to investigate whether acute exacerbations reported as serious adverse events were associated with higher mortality than those reported as non-serious adverse events and to assess the effect of nintedanib on these types of events.
Methods: Adverse events considered by an investigator to be an acute exacerbation were adjudicated as a confirmed acute exacerbation, suspected acute exacerbation, or not an acute exacerbation.